The estimated Net Worth of Fredric N Eshelman is at least $9.38 Миллион dollars as of 29 January 2018. Fredric Eshelman owns over 335,000 units of G1 Therapeutics Inc stock worth over $9,079,542 and over the last 9 years he sold GTHX stock worth over $0. In addition, he makes $296,673 as Independent Director at G1 Therapeutics Inc.
Sign up
Fredric Eshelman GTHX stock SEC Form 4 insiders trading
Fredric has made over 6 trades of the G1 Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 335,000 units of GTHX stock worth $3,350,000 on 29 January 2018.
The largest trade he's ever made was buying 621,720 units of G1 Therapeutics Inc stock on 6 December 2016 worth over $20,995,484. On average, Fredric trades about 91,215 units every 29 days since 2015. As of 29 January 2018 he still owns at least 1,273,428 units of G1 Therapeutics Inc stock.
You can see the complete history of Fredric Eshelman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Fredric Eshelman biography
Dr. Fredric (Fred) N. Eshelman serves as Independent Director of the Company. Dr. Eshelman founded Eshelman Ventures, LLC in March 2014, which invests in a variety of companies, primarily in the healthcare sector, and has served as a principal since its founding. Dr. Eshelman served as Chief Executive Officer for Pharmaceutical Product Development, Inc., a contract research organization, from June 1990 to December 2011, as Senior Vice President, Development and a member of the board of directors of the former Glaxo Inc., a pharmaceutical company, from 1989 to 1990. He currently serves as chairman of the board of Eyenovia, Inc. a publicly traded biopharmaceutical company, where he has been a member of the board of directors since December 2014. In April 2020, Dr. Eshelman was appointed to the board of directors and became chairman of the board of Aravive, Inc. a publicly traded biotechnology company. Previously, Dr. Eshelman served as the chairman of the board of directors of The Medicines Company, a publicly traded biopharmaceutical company. He has served on the board of directors of Valeant Pharmaceuticals International, Inc. (now known as Bausch Health), a publicly traded Canadian pharmaceutical company, since March 2016. Dr. Eshelman previously served on the board of directors of Furiex Pharmaceuticals, a publicly traded biopharmaceutical company, from 2010 until July 2014, when it was sold to Forest Labs/Actavis, and of Pharmaceutical Product Development, Inc., a contract research organization that was publicly traded until 2011, from 1986 until 2011. He also serves on the boards of directors of a number of privately held biopharmaceutical companies. Dr. Eshelman also served on the executive committee of the Medical Foundation of North Carolina, the board of the North Carolina Biotechnology Center, and the Board of Trustees for the University of North Carolina System. In addition, Dr. Eshelman serves as an adjunct professor at the University of North Carolina at Chapel Hill School of Pharmacy, where he chairs
What is the salary of Fredric Eshelman?
As the Independent Director of G1 Therapeutics Inc, the total compensation of Fredric Eshelman at G1 Therapeutics Inc is $296,673. There are 17 executives at G1 Therapeutics Inc getting paid more, with Mark Avagliano having the highest compensation of $5,478,390.
How old is Fredric Eshelman?
Fredric Eshelman is 72, he's been the Independent Director of G1 Therapeutics Inc since 2015. There are no older and 26 younger executives at G1 Therapeutics Inc.
What's Fredric Eshelman's mailing address?
Fredric's mailing address filed with the SEC is C/O EYENOVIA, INC., 295 MADISON AVENUE, SUITE 2400, NEW YORK, NY, 10017.
Insiders trading at G1 Therapeutics Inc
Over the last 7 years, insiders at G1 Therapeutics Inc have traded over $53,962,020 worth of G1 Therapeutics Inc stock and bought 1,541,753 units worth $24,259,954 . The most active insiders traders include Capital Management, L.P.Ra ..., Fredric N Eshelman и Glenn P Muir. On average, G1 Therapeutics Inc executives and independent directors trade stock every 17 days with the average trade being worth of $198,620. The most recent stock trade was executed by Andrew Perry on 5 July 2024, trading 1,337 units of GTHX stock currently worth $3,356.
What does G1 Therapeutics Inc do?
g1 therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. the company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates.
What does G1 Therapeutics Inc's logo look like?
Complete history of Fredric Eshelman stock trades at G1 Therapeutics Inc и Eyenovia Inc
G1 Therapeutics Inc executives and stock owners
G1 Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Mark Avagliano,
Chief Business Officer -
James Hanson,
General Counsel, Secretary -
Mark Velleca,
President, Chief Executive Officer, Director -
Terry Murdock,
Chief Operating Officer -
Garry Nicholson,
Independent Chairman of the Board -
Jennifer Moses,
Chief Financial Officer -
Rajesh Malik,
Chief Medical Officer, Senior Vice President - Research and Development -
Dr. Mark A. Velleca M.D., Ph.D.,
Sr. Advisor & Director -
Mark Avagliano,
Chief Bus. Officer -
Dr. Rajesh K. Malik Ch.B., M.B., M.D.,
Chief Medical Officer and Sr. VP of R&D -
Dr. Rajesh K. Malik,
Chief Medical Officer and Sr. VP of R&D -
Andrew Perry,
Chief Commercial Officer -
Jennifer K. Moses CPA,
Chief Financial Officer -
Jennifer K. Moses,
Chief Financial Officer -
Seth Rudnick,
Independent Director -
Glenn Muir,
Independent Director -
Cynthia Schwalm,
Independent Director -
Fredric Eshelman,
Independent Director -
Willie Deese,
Independent Director -
Andrew Witty,
Independent Director -
John Bailey,
Independent Director -
Soma Gupta,
Chief Commercial Officer -
Jay Strum,
Chief Scientific Officer -
Terry L. Murdock,
Chief Operating Officer -
Blake Jensen,
VP of Quality & Compliance -
William C. Roberts,
VP of Investor Relations & Corp. Communications -
Dr. Jay C. Strum,
Chief Scientific Officer -
Alexander D. Smith M.S.,
VP of Technical Operations -
John E. Bailey Jr.,
CEO, Pres & Director -
Clay Hatteras Venture Advis...,
-
Capital Management, L.P.Ra ...,
-
Christy L Shaffer,
Director -
Ventures, Inc. Med Immune,
10% owner -
Ventures, Llc Eshelman,
10% owner -
Clay Hatteras Venture Advis...,
-
Barclay A Phillips,
SVP & Chief Financial Officer -
Monica R. Thomas,
Chief Legal & People Officer -
Jacks Lee,
-
John Demaree,
Chief Commercial Officer -
Alicia Secor,
-
Cynthia Louise Flowers,
-
Andrew Perry,
Chief Commercial Officer -
Norman Sharpless,
-
John W. V Umstead,
Chief Financial Officer